Scabies: Permethrin Resistance and Role of Ivermectin. Results of An Italian Consensus


Italian journal of dermatology and venereology  ·  2026

Laura Atzori; Riccardo Balestri; Andrea Bassi; Carlo Mazzatenta; Giuseppe Micali; Manuela Papini; Stefano Ramoni; Gaetano Scanni; Stefano Veraldi;

RELATED
Papers      Patents     Grants     Venues     Experts    Cite    Share    Save


ABSTRACT
Resistance to permethrin in patients with scabies emerged in recent years both in Italy and in the rest of Europe. A panel of nine Italian dermatologists with expertise in scabies was convened to address 23 questions regarding scabies therapy. Only agreement/disagreement responses were accepted. A unanimous conclusion emerged: permethrin should no longer be considered as first-line therapy for scabies in Italy. Benzyl benzoate was considered a reasonable alternative by two-thirds of the experts, although concentration and optimal formulation remain unclear and warrant further investigation. Full agreement was reached about ivermectin as first-line therapy. Ivermectin should be considered as the therapy of choice in patients with scabies.

 Paraphrase     Questionfy     Wikify     Simplify     Summarize


year_of_publication2026
sourceItalian journal of dermatology and venereology

AI Reader
upload a document and start your AI-powered reading
AI Writer
you focus on what matters the most, we handle the rest
Daily Digest
get customized highlights of the latest research & news